Becton Dickinson (LTS:0R19) ROCE %: 1.70% (As of Mar. 2026)


LTS:0R19 Becton Dickinson & Co LTS:0R19
76 GF Score
Price $145.59
GF Value $190.16
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Becton Dickinson ROCE %?

Becton Dickinson LTS:0R19 +2.75% 76 ROCE % is 1.70% as of Mar. 2026. GuruFocus rates LTS:0R19 with a GF Score™ of 76/100 and a GF Value™ of $190.16 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Becton Dickinson's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.70%.

Becton Dickinson  (LTS:0R19) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Becton Dickinson ROCE % Related Terms

Becton Dickinson ROCE % Historical Data

* Premium members only.

The historical data trend for Becton Dickinson's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Becton Dickinson ROCE % Chart

Becton Dickinson Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.53 4.72 4.63 5.36 5.23

Becton Dickinson Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.99 7.31 5.67 4.69 1.70
LTS:0R19
76GF Score
Becton Dickinson & Co LTS:0R19
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Becton Dickinson ROCE % Calculation

Becton Dickinson's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=2494/( ( (57286 - 8956) + (55325 - 8313) )/ 2 )
=2494/( (48330+47012)/ 2 )
=2494/47671
=5.23 %

Becton Dickinson's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=752/( ( (54841 - 8761) + (50832 - 8507) )/ 2 )
=752/( ( 46080 + 42325 )/ 2 )
=752/44202.5
=1.70 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 1.70% mean?
Becton Dickinson (LTS:0R19) has a ROCE % of 1.70% as of Mar. 2026.
Is Becton Dickinson's ROCE % too high?
Becton Dickinson's current ROCE % is 1.70%. The Medical Devices & Instruments industry median ROCE % is 2.23. Becton Dickinson's value of 1.70% is 23.8% below this industry median. Overall, Becton Dickinson has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's ROCE % compare to MDLN and RMD?
Becton Dickinson's ROCE % of 1.70% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Becton Dickinson's value of 1.70% is 23.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Becton Dickinson's current ROCE % of 1.70% is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Becton Dickinson's current ROCE % is 1.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Based on GuruFocus' analysis, Becton Dickinson (LTS:0R19) is currently considered Modestly Undervalued. The stock's GF Value™ is $190.16, compared to a current price of $145.59 — trading 23.4% below its estimated fair value. The current ROCE % is 1.70% and 23.8% below the Medical Devices & Instruments industry median of 2.23. Becton Dickinson's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Becton Dickinson (LTS:0R19), the current ROCE % is 1.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Becton Dickinson (LTS:0R19) Overvalued in 2026?

Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued. The current stock price of $145.59 is trading 23.4% below its estimated GF Value™ of $190.16. GuruFocus considers Becton Dickinson to be Modestly Undervalued.

Key valuation signals for LTS:0R19:

  • ROCE %: 1.70%
  • GF Value™: $190.16 vs. price of $145.59 (23.4% below fair value)
  • GF Score™: 76/100 with 3 warning signs
  • Industry Position: 23.8% below the Medical Devices & Instruments median

No single metric tells the full story. See the LTS:0R19 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Becton Dickinson Business Description

Address 1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
76GF Score

Get the complete analysis for LTS:0R19

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$145.59
Price
$190.16
GF Value